UK drugmaker Vernalis has signed a drug discovery deal with Daiichi Sankyo Co that aims to find new targets for potential cancer therapies.
Detail on the deal is thin, but it was disclosed that the collaboration will use Vernalis’ fragment and structure-based drug discovery platform against undisclosed oncology targets.
Financial terms of the alliance were also kept under wraps for now.
Ian Garland, Vernalis’ chief executive, said the firm is “delighted to be working with Daiichi Sankyo on this project.
“This is another excellent endorsement of our market leading fragment and structure-based drug discovery platform and we look forward to a successful collaboration with Daiichi Sankyo.”